Citius Oncology (CTOR) Operating Income (2023 - 2026)

Citius Oncology's Operating Income history runs 4 years deep, the most recent figure standing at -$28.6 million for Q1 2026.

• In Q1 2026, Operating Income fell 282.98% year-over-year to -$28.6 million; the TTM figure through Mar 2026 stood at -$43.5 million (down 131.95% YoY), while the FY2025 annual figure was -$23.5 million, down 14.34% from the prior year.
• Operating Income was -$28.6 million for Q1 2026 at Citius Oncology, down from -$5.3 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$147922.0 in Q1 2023 to a low of -$28.6 million in Q1 2026.
• Historically, Operating Income has averaged -$5.7 million across 4 years, with a median of -$4.7 million in 2025.
• Biggest YoY gain for Operating Income was 17.87% in 2025; the steepest drop was 2683.35% in 2025.
• A 4-year view of Operating Income shows it stood at -$421455.0 in 2023, then tumbled by 1417.35% to -$6.4 million in 2024, then advanced by 17.87% to -$5.3 million in 2025, then tumbled by 444.78% to -$28.6 million in 2026.
• The last three Operating Income figures came in at -$28.6 million (Q1 2026), -$5.3 million (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.